Accession Number : ADA589544


Title :   Probing Androgen Receptor Signaling in Circulating Tumor Cells in Prostate Cancer


Descriptive Note : Annual summary rept. 1 Jul 2012-30 Jun 2013


Corporate Author : MASSACHUSETTS GENERAL HOSPITAL BOSTON


Personal Author(s) : Miyamoto, David T


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a589544.pdf


Report Date : Jul 2013


Pagination or Media Count : 38


Abstract : This Award focuses on using a novel microfluidic CTC-chip to capture and measure androgen receptor (AR) activity in circulating tumor cells (CTCs) in prostate cancer patients before and after hormonal therapy. During the first year of this award, we have successfully developed a quantitative immunofluorescence assay to measure AR activity in single CTCs, and have piloted this assay in men with metastatic prostate cancer receiving treatment with hormonal therapy. Preliminary results suggest that this novel assay can effectively measure AR activity levels in CTCs, and that CTC AR activity at baseline and after therapy may be correlated with treatment outcomes. Thus, this CTC-based assay may serve as a non-invasive biomarker that can potentially help guide therapy in prostate cancer. These initial results were published during this term in Cancer Discovery. Ongoing efforts include single CTC transcriptional profiling to better understand heterogeneity of metastatic precursor cells and uncover alternative signaling pathways that may be activated in castration-resistant prostate cancer.


Descriptors :   *ANDROGENS , *CELLS(BIOLOGY) , *PROSTATE CANCER , *RECEPTOR SITES(PHYSIOLOGY) , HETEROGENEITY , HORMONES , METASTASIS , NEOPLASMS , PATIENTS , SENSE ORGANS , TRANSCRIPTION(GENETICS)


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE